Skip to main content
Matthew Wieduwilt, MD, Oncology, San Diego, CA, UC San Diego Medical Center - Hillcrest

MatthewJosephWieduwiltMD

Oncology San Diego, CA

Assistant Professor, Medicine, UCSD School of Medicine

Dr. Wieduwilt is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Wieduwilt's full profile

Already have an account?

Education & Training

  • University of California (San Francisco)
    University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2008 - 2011
  • University of California (San Francisco)
    University of California (San Francisco)Residency, Internal Medicine, 2005 - 2008
  • University of Texas Southwestern Medical School
    University of Texas Southwestern Medical SchoolClass of 2005

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 2022 - 2025
  • CA State Medical License
    CA State Medical License 2007 - 2023
  • OK State Medical License
    OK State Medical License 2021 - 2023

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematolo...
    Matthew J. Wieduwilt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Anal...
    Matthew J. Wieduwilt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • A Phase 1b Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
    Matthew J. Wieduwilt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Expert Discussion and Guidance on New Advances, Clinical Opportunities, and Current Challenges in Treating Adults with Ph-Negative Acute Lymphoblastic Leukemia 
    60th American Society of Hematology Annual Meeting - 11/30/2018

Press Mentions

  • Combination Therapy Achieves High Response in Ph+ ALL
    Combination Therapy Achieves High Response in Ph+ ALLJune 5th, 2021
  • Young Chula Vista Man’s Blood Cancer Diagnosis Example of Challenges Facing Vulnerable Age Group
    Young Chula Vista Man’s Blood Cancer Diagnosis Example of Challenges Facing Vulnerable Age GroupSeptember 30th, 2019
  • Inotuzumab Ozogamicin, Blinatumomab May Be Superior to Chemotherapy in Some Elderly Patients with B-cell ALL
    Inotuzumab Ozogamicin, Blinatumomab May Be Superior to Chemotherapy in Some Elderly Patients with B-cell ALLJune 5th, 2023

Hospital Affiliations